PMID- 29398466
OWN - NLM
STAT- MEDLINE
DCOM- 20200520
LR  - 20210525
IS  - 2173-5743 (Electronic)
IS  - 2173-5743 (Linking)
VI  - 15
IP  - 6
DP  - 2019 Nov-Dec
TI  - Relationship between fecal calprotectin, anti-Saccharomyces cerevisiae antibodies 
      and other markers of disease activity in patients with spondyloarthritis.
PG  - 360-362
LID - S1699-258X(17)30301-7 [pii]
LID - 10.1016/j.reuma.2017.11.013 [doi]
AB  - OBJECTIVE: To assess the relationship between the increase of fecal calprotectin, 
      anti-Saccharomyces cerevisiae antibodies (ASCA) and disease markers in a group of 
      patients with spondyloarthritis. METHODS: We evaluated patients who were at least 
      18-years-old and met the Assessment in Spondyloarthritis International Society 
      (ASAS) criteria for spondyloarthritis or the New York modified criteria. We 
      analyzed activity criteria, physical function, analytical criteria (human 
      leukocyte antigen [HLA] B27, fecal calprotectin, presence of ASCA, among others) 
      and demographic data. RESULTS: We included 33 patients. All but one patient had 
      normal ASCA values. We found statistical significance in the correlation of 
      calprotectin with C-reactive protein (CRP) but not with other parameters. We also 
      found a relationship between calprotectin levels and nonsteroidal 
      anti-inflammatory drug (NSAID) intake (P=.001). We found no relationship between 
      CRP levels and NSAID use. After discontinuation of NSAIDs for one month, we found 
      no significant differences in calprotectin levels (P=.9). CONCLUSION: Fecal 
      calprotectin is elevated in patients with spondyloarthritis and correlates 
      positively with CRP. Level of fecal calprotectin is not altered by NSAID use. The 
      amount of ASCA present does not change and does not correlate with any clinical 
      parameters in the study population.
CI  - Copyright (c) 2017 Elsevier Espana, S.L.U. and Sociedad Espanola de Reumatologia y 
      Colegio Mexicano de Reumatologia. All rights reserved.
FAU - Moreno Martinez, Maria Jose
AU  - Moreno Martinez MJ
AD  - Reumatologia, Hospital Rafael Mendez, Lorca, Murcia, Espana. Electronic address: 
      mjmorenomartinez@gmail.com.
FAU - Moreno Ramos, Manuel Jose
AU  - Moreno Ramos MJ
AD  - Reumatologia, Hospital Virgen de la Arrixaca, Murcia, Espana.
FAU - Linares Ferrando, Luis Francisco
AU  - Linares Ferrando LF
AD  - Reumatologia, Hospital Rafael Mendez, Lorca, Murcia, Espana; Reumatologia, 
      Hospital Virgen de la Arrixaca, Murcia, Espana.
LA  - eng
LA  - spa
PT  - Journal Article
TT  - Relacion de calprotectina fecal y anti saccharomyces antisacaromices con otros 
      marcadores de actividad en pacientes con espondiloartritis.
DEP - 20180215
PL  - Spain
TA  - Reumatol Clin (Engl Ed)
JT  - Reumatologia clinica
JID - 101717526
RN  - 0 (Antibodies, Fungal)
RN  - 0 (Biomarkers)
RN  - 0 (Leukocyte L1 Antigen Complex)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adult
MH  - Antibodies, Fungal/*blood
MH  - Biomarkers/analysis
MH  - C-Reactive Protein/analysis
MH  - Feces/*chemistry
MH  - Humans
MH  - Leukocyte L1 Antigen Complex/*analysis
MH  - Middle Aged
MH  - Saccharomyces cerevisiae/*immunology
MH  - Spondylarthritis/blood/*diagnosis/*metabolism
OTO - NOTNLM
OT  - Anti-inflammatory drugs
OT  - Antiinflamatorios
OT  - Calprotectin
OT  - Calprotectina
OT  - Espondiloartritis
OT  - Inflamacion
OT  - Inflammation
OT  - Spondyloarthritis
EDAT- 2018/02/06 06:00
MHDA- 2020/05/21 06:00
CRDT- 2018/02/06 06:00
PHST- 2017/07/09 00:00 [received]
PHST- 2017/10/10 00:00 [revised]
PHST- 2017/11/26 00:00 [accepted]
PHST- 2018/02/06 06:00 [pubmed]
PHST- 2020/05/21 06:00 [medline]
PHST- 2018/02/06 06:00 [entrez]
AID - S1699-258X(17)30301-7 [pii]
AID - 10.1016/j.reuma.2017.11.013 [doi]
PST - ppublish
SO  - Reumatol Clin (Engl Ed). 2019 Nov-Dec;15(6):360-362. doi: 
      10.1016/j.reuma.2017.11.013. Epub 2018 Feb 15.